{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:51:20Z","timestamp":1785855080266,"version":"3.56.0"},"reference-count":87,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Approximately 80% of breast cancers are estrogen receptor positive, and following initial tumor treatment, patients are prescribed hormone therapy (HT) drugs (tamoxifen, letrozole, anastrozole, and exemestane) for 5-10 years. These drugs are known to cause several side effects. Additionally, a small number of studies have identified that changing medication brands (generics) can negatively affect patients\u2019 side effects, attitudes, and acceptance of HT. However, no effective intervention currently exists to address patients\u2019 concerns about generic switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study explores whether a symptom diary appears to be an acceptable approach for patients and pharmacists to address brand concerns, and provides a detailed report of the planning and development stages of a coproduced diary intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This paper presents the studies conducted during the planning and development stages of the symptom diary, following the person-based approach, which combines theory-, evidence-, and person-based approaches to ensure interventions are acceptable and easy to implement. The study included the following stages: (1) the planning stage, which involved analysis of an online patient forum (n=277), interviews with patients (n=9), and interviews with pharmacists (n=7). Data triangulation was used to present an integrated set of findings. (2) The development stage, which involved a rapid scoping review of the literature on the use of diaries among patients with cancer, coproduction workshops with patients and pharmacists (n=17), pharmacist interviews (n=11), and consultation with our patient advisory group (n=5). Analysis was informed by evidence synthesis, behavior change analyses, and iterative stakeholder consultations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the intervention planning stage, patients and pharmacists perceived community pharmacies as the ideal setting for HT medication consultations. Both groups proposed using a patient diary to support awareness and attribution of drug-related symptoms. Pharmacists described patients\u2019 requests for specific brands as difficult to manage, whereas patients reported that switching brands undermined confidence in medication-taking. In the development stage, the scoping review (n=29 papers) identified barriers and facilitators related to diary use, and workshops explored diary format and content. These findings informed the intervention planning table and the first diary prototype. Pharmacist interviews and patient feedback informed the development of 2 further prototypes. The symptom diary is a self-monitoring tool designed to enhance self-efficacy in HT medication-taking behaviors. It includes recording side effects from brands alongside physical, psychological, and environmental factors; actions taken to manage symptoms; and problem-solving and planning before a medication consultation to facilitate personalized feedback from pharmacists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We preliminarily developed an intervention that appears engaging, relevant, and acceptable for patients to self-monitor their symptoms. Further revisions informed by user feedback will be incorporated after testing ENABLE (Medication Brand Changes in Hormone Therapy for Breast Cancer: A Community Pharmacy Intervention Development to Improve Patients\u2019 Adherence and Quality of Life) in community pharmacies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>ISRCTN Registry ISRCTN15089342; http:\/\/www.isrctn.com\/ISRCTN15089342<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/91234","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T19:25:06Z","timestamp":1779823506000},"page":"e91234","source":"Crossref","is-referenced-by-count":0,"title":["Planning and Developing a Symptom Diary Intervention for Breast Cancer Survivors With Concerns About Medication Brands (ENABLE Study): User-Centered Design Approach"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-5960","authenticated-orcid":false,"given":"Yolanda","family":"Eraso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7355-4280","authenticated-orcid":false,"given":"Duncan","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1431-2772","authenticated-orcid":false,"given":"Ruth","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9371-2224","authenticated-orcid":false,"given":"Bal","family":"Nanray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6673-7544","authenticated-orcid":false,"given":"Jacqueline","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref1","unstructured":"Breast cancer statisticsCancer Research UK20252026-01-25https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer#breastcs0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.05.005"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz298"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.01.012"},{"key":"ref5","unstructured":"National Institute for Health and Care Excellence (NICE)British National Formulary (BNF)NICE BNF20252026-01-25https:\/\/bnf.nice.org.uk\/"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2010.02.004"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.07.001"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6753"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211020805"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2015.10.003"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10122558"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07658-x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s145784"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2019.101706"},{"key":"ref15","unstructured":"Royal Pharmaceutical SocietyUtilising community pharmacists to support people with cancerRoyal Pharmaceutical Society202001102025-11-25https:\/\/www.rpharms.com\/recognition\/all-our-campaigns\/policy-a-z\/cancer-support"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007768.pub3"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.11.008"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12554"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s40814-015-0033-z"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2061"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9060688"},{"key":"ref22","author":"Smith, J","year":"2009","journal-title":"Interpretative Phenomenological Analysis: Theory, Method and Research"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305276687"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-017-0605-9"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305285708"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033516"},{"key":"ref28","author":"Bandura, A","year":"1986","journal-title":"Social Foundations of Thought and Action. A Social Cognitive Theory"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2269-1"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010107"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1521\/jscp.1986.4.3.359"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.06.010"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-012-2387-8"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104510"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-3991(02)00032-0"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213432"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4959"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13722"},{"key":"ref39","unstructured":"Cancer in the UK 2025: socioeconomic deprivationCancer Research UK20252025-11-27https:\/\/www.cancerresearchuk.org\/sites\/default\/files\/cancer_in_the_uk_2025_socioeconomic_deprivation.pdf"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-01","author":"Aromataris, E","year":"2024","journal-title":"JBI Manual for Evidence Synthesis"},{"key":"ref41","unstructured":"ErasoYCochraneJStewartSEdwardsRNanrayBDiary interventions and self-monitoring behaviours in cancer survivors. A rapid scoping review protocolLondon Metropolitan University2025012025-11-15https:\/\/repository.londonmet.ac.uk\/id\/eprint\/10517"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/0261018317747444"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-106459"},{"key":"ref44","unstructured":"Guidance on co-producing a research projectNIHR2021042025-11-20https:\/\/www.learningforinvolvement.org.uk\/wp-content\/uploads\/2021\/04\/NIHR-Guidance-on-co-producing-a-research-project-April-2021.pdf"},{"key":"ref45","unstructured":"Theory and technique toolHuman Behaviour Change Project20222026-01-15https:\/\/theoryandtechniquetool.humanbehaviourchange.org\/"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-019-0169-8"},{"key":"ref47","unstructured":"World Health Organization (WHO)Adherence to long-term therapies: evidence for actionWHO20032026-01-13https:\/\/iris.who.int\/handle\/10665\/42682"},{"key":"ref48","unstructured":"Advanced Service Specification - NHS New Medicine Service (NMS)National Health Service (NHS)20212025-09-13https:\/\/www.england.nhs.uk\/publication\/advanced-service-specification-nhs-new-medicine-service-nms\/"},{"key":"ref49","unstructured":"NHS Prescription ServicesNational Health Service (NHS)2025-09-13https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/prescribing-and-dispensing"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1057\/sth.2013.10"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1123\/jpah.7.6.794"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-016-0528-5"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gerinurse.2013.09.007"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/jan.12978"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1177\/15347354211069885"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.2196\/cancer.8951"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35264"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018015"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1188\/22.CJON.283-292"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2018-000039"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2014.04.012"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kaad049"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1111\/jhn.13008"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-1267"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.01.015"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S187692"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2021.100768"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151514"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5868-10-124"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/pon.5252"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5329-5"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1097\/ncc.0000000000000699"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3747\/co.v15i6.378"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.03.010"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1260-1"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2015.01.007"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01406-1"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-057664"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.2196\/34833"},{"key":"ref80","unstructured":"Standards for pharmacy professionalsGeneral Pharmaceutical Council2017052025-07-30https:\/\/assets.pharmacyregulation.org\/files\/standards_for_pharmacy_professionals_may_2017_0.pdf?VersionId=C8dRrU1opDLdsuveSss5cKsPSwKObTi2"},{"key":"ref81","unstructured":"Shared decision makingNational Institute for Health and Care Excellence (NICE)2026-04-20https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-guidelines\/shared-decision-making"},{"key":"ref82","unstructured":"Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherenceNational Institute for Health and Care Excellence  (NICE)20092025-08-27https:\/\/www.nice.org.uk\/guidance\/cg76\/chapter\/Recommendations#reviewing-medicines"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa083"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2024.100514"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2022.102183"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-020-0528-9"},{"key":"ref87","unstructured":"Open Science Framework (OSF)2026-05-14https:\/\/10.17605\/OSF.IO\/3TMJ4"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e91234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:01:06Z","timestamp":1785852066000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e91234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":87,"URL":"https:\/\/doi.org\/10.2196\/91234","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.91234","asserted-by":"object"}]},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}